2O9A Stock Overview Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Renalytix Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Renalytix Historical stock prices Current Share Price UK£0.65 52 Week High UK£3.52 52 Week Low UK£0.22 Beta 1.98 1 Month Change 0% 3 Month Change -7.14% 1 Year Change -65.43% 3 Year Change -97.48% 5 Year Change n/a Change since IPO -95.00%
Recent News & Updates
Renalytix Plc Appoints Robert Naylor as Non-Executive Director Dec 02
Renalytix Plc, Annual General Meeting, Dec 19, 2024 Nov 27
Renalytix Plc Provides Revenue Guidance for Years 2025, 2026 and 2027 Nov 20
Renalytix Plc announced delayed 10-Q filing Nov 15
Renalytix plc Announces Board Changes Nov 05
Renalytix plc Announces Step Down of Dan Levangie, Non-Executive Director from the Board Nov 01 See more updates
Renalytix Plc Appoints Robert Naylor as Non-Executive Director Dec 02
Renalytix Plc, Annual General Meeting, Dec 19, 2024 Nov 27
Renalytix Plc Provides Revenue Guidance for Years 2025, 2026 and 2027 Nov 20
Renalytix Plc announced delayed 10-Q filing Nov 15
Renalytix plc Announces Board Changes Nov 05
Renalytix plc Announces Step Down of Dan Levangie, Non-Executive Director from the Board Nov 01
Renalytix Plc(OTCPK:RNLX.Y) dropped from NASDAQ Composite Index Oct 08 Renalytix Plc has completed a Follow-on Equity Offering in the amount of £11.80454 million.
Nasdaq Grants Listing Extension to Renalytix Aug 27
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Jun 29
Renalytix Provides Non-Compliance Update Jun 25
Renalytix Plc Announces Chief Financial Officer Changes May 29 Renalytix Plc Reports Impairment Loss on Property, Equipment and Other Long-Lived Assets for the Third Quarter Ended March 31, 2024
Renalytix Plc to Report Q3, 2024 Results on May 15, 2024 May 10
Renalytix plc Announces Executive Changes, Effective from April 30, 2024 Apr 19 Renalytix Plc has filed a Follow-on Equity Offering in the amount of $1 million. Apr 10
Renalytix Plc has filed a Follow-on Equity Offering in the amount of $4 million. Apr 08
Renalytix Plc, Annual General Meeting, Apr 22, 2024 Mar 30
Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease Mar 15 Renalytix Plc has filed a Follow-on Equity Offering in the amount of £7.8 million. Renalytix Plc has filed a Follow-on Equity Offering in the amount of £7.8 million. Mar 12
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for Renalytix Plc's Kidneyintelx and Kidneyintelx.Dkd Feb 09
Renalytix plc Announces Update on Kidneyintelx.Dkd Local Coverage Determination Consideration Jan 17
Renalytix Receives Non-Compliance Notice From Nasdaq Dec 31
Renalytix Receives Non-Compliance Notice From Nasdaq Dec 30
Renalytix plc Announces Step Down of Chirag Parikh as Independent Non-Executive Director Dec 09
Renalytix Plc to Report Q1, 2024 Results on Nov 14, 2023 Nov 07
Renalytix Plc, Annual General Meeting, Dec 15, 2023 Oct 31
Renalytix Plc Announces the Stepped Down of Timothy Scannell as Independent Non-Executive Director Oct 24
Renalytix Plc to Report Second Half, 2023 Results on Sep 28, 2023 Sep 25
Renalytix plc Announces the Appointment of Howard Doran as Chief Business Officer Sep 08
Renalytix plc Announces Appointments to Its Clinical Advisory Board Aug 04
Renalytix Plc Announces Late-Breaking KidneyIntelX Evidence Released at American Diabetes Association Scientific Sessions Jul 08
Renalytix plc Appoints Catherine Coste to Board of Directors, Non-Executive Chair of the Audit Committee and a Member of the Remuneration Committee Jul 04
Fda Grants De Novo Marketing Authorization for Kidneyintelx.Dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease of Renalytix plc Jul 01
Renalytix Plc Announces KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Jun 16
New major risk - Financial position Jun 12
Renalytix Plc to Report Q3, 2023 Results on Jun 09, 2023 Jun 05 Renalytix Plc, Annual General Meeting, Jun 08, 2023 May 12
Renalytix plc Announces the Launch of PRIME-CKD Jan 28
Renalytix plc Announces That Primary Care Use of Kidneyintelx in Early Stage Ckd Improved Clinical Care Delivery and Outcomes Dec 02
Renalytix Plc to Report Q1, 2023 Results on Nov 30, 2022 Nov 22
Renalytix Plc, Annual General Meeting, Dec 19, 2022 Nov 10
Renalytix Plc to Report Q4, 2022 Results on Oct 31, 2022 Oct 25
Renalytix plc Announces Ann Berman, Non-Executive Director and Chair of the Audit and Nomination Committees, Resigns as Director Sep 20
Renalytix Plc Announces Publication of Clinical Utility Study in The AJMC Aug 08
Renalytix Plc to Report Q3, 2022 Results on Jun 30, 2022 Jun 23
Renalytix Plc Announces 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Jun 11 Renalytix Helds Two Data Presentations on Kidneyintelx at American Diabetes Association 82nd Scientific Sessions Renalytix Plc announced that it expects to receive $21.2 million in funding from Heights Capital Ireland, Llc Apr 01
Renalytix plc Reaches Enrollment Milestone for Building Kidneyintelx as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Renalytix plc Announces the Launch of Its New Provider Access Portal, myIntelX Mar 10 Renalytix plc Announces the Presentation of New Clinical Data for KidneyIntelX Bioprognostictm Testing At the World Congress of Nephrology Annual Meeting
Renalytix Announces Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy Jan 12
Renalytix plc Announces Scaled-Up Implementation of the KidneyIntelX Sep 15
Renalytix plc Announces Publication of Results from an External Chronic Kidney Disease Budget Impact Analysis Aug 27
Renalytix AI plc Announces Results from New Utility Study that Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care Jun 03
Renalytix AI plc and the University of Utah Announce Partnership Feb 25
Renalytix AI plc to Report First Half, 2021 Results on Mar 02, 2021 Feb 23
Renalytix AI plc Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Jan 13
Renalytix AI plc and DaVita Announce Partnership Jan 05
Nkf and Renalytixai Partner to Improve Management of Early Stage Kidney Disease Dec 03
Renalytix AI plc, Annual General Meeting, Dec 07, 2020 Nov 04 Shareholder Returns 2O9A DE Healthcare Services DE Market 7D 0% -0.6% -0.02% 1Y -65.4% -12.5% 15.1%
See full shareholder returns
Return vs Market: 2O9A underperformed the German Market which returned 4.2% over the past year.
Price Volatility Is 2O9A's price volatile compared to industry and market? 2O9A volatility 2O9A Average Weekly Movement n/a Healthcare Services Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2O9A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2O9A's volatility change over the past year.
About the Company Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Show more Renalytix Plc Fundamentals Summary How do Renalytix's earnings and revenue compare to its market cap? 2O9A fundamental statistics Market cap €41.49m Earnings (TTM ) -€34.48m Revenue (TTM ) €2.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2O9A income statement (TTM ) Revenue US$2.22m Cost of Revenue US$2.26m Gross Profit -US$35.00k Other Expenses US$37.45m Earnings -US$37.49m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -0.24 Gross Margin -1.58% Net Profit Margin -1,687.80% Debt/Equity Ratio -84.1%
How did 2O9A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/05/18 05:31 End of Day Share Price 2024/02/20 00:00 Earnings 2024/03/31 Annual Earnings 2023/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Renalytix Plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anita Dushyanth Berenberg Mark Massaro BTIG David Westenberg Guggenheim Securities, LLC
Show 3 more analysts 
